GNLX GENELUX Corp

Nasdaq www.genelux.com


$ 7.72 $ 1.39 (22.03 %)    

Thursday, 23-Oct-2025 16:36:43 EDT
QQQ $ 611.33 $ 5.68 (0.94 %)
DIA $ 466.73 $ 1.78 (0.38 %)
SPY $ 671.88 $ 3.53 (0.53 %)
TLT $ 91.47 $ -0.15 (-0.16 %)
GLD $ 378.62 $ -2.69 (-0.71 %)
$ 6.31
$ 6.31
$ 7.71 x 460
$ 7.90 x 700
$ 6.31 - $ 8.04
$ 1.99 - $ 6.85
260,489
na
238.35M
$ 0.24
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-06-2025 03-31-2025 10-Q
3 03-28-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-14-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-29-2024 12-31-2023 10-K
8 11-14-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 03-29-2023 12-31-2022 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 lake-street-initiates-coverage-on-genelux-with-buy-rating-announces-price-target-of-16

Lake Street analyst Chad Messer initiates coverage on Genelux (NASDAQ:GNLX) with a Buy rating and announces Price Target of ...

 genelux-q2-eps-020-beats-022-estimate

Genelux (NASDAQ:GNLX) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.22) by 9....

 lucid-capital-markets-initiates-coverage-on-genelux-with-buy-rating-announces-price-target-of-10

LUCID CAPITAL MARKETS analyst Christopher Liu initiates coverage on Genelux (NASDAQ:GNLX) with a Buy rating and announces Pr...

 benchmark-maintains-speculative-buy-on-genelux-lowers-price-target-to-23

Benchmark analyst Bruce Jackson maintains Genelux (NASDAQ:GNLX) with a Speculative Buy and lowers the price target from $25 ...

 hc-wainwright--co-reiterates-buy-on-genelux-maintains-30-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates Genelux (NASDAQ:GNLX) with a Buy and maintains $30 price target.

 hc-wainwright--co-reiterates-buy-on-genelux-maintains-30-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates Genelux (NASDAQ:GNLX) with a Buy and maintains $30 price target.

 genelux-concluded-meeting-with-fda-for-oli-vec-in-treatment-of-prroc

In response to a question seeking the FDA's guidance on their expectations regarding a confirmatory trial using the ongoing...

 genelux-and-newsoara-announce-preliminary-phase-1b2-data-of-olvi-vec-in-advanced-small-cell-lung-cancer

  Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two...

 genelux-corp-tapped-matthew-pulisic-of-arrowhead-pharma-as-cfo-effective-january-30

Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that Matthew Pulisic has join...

 hc-wainwright--co-maintains-buy-on-genelux-lowers-price-target-to-30

HC Wainwright & Co. analyst Emily Bodnar maintains Genelux (NASDAQ:GNLX) with a Buy and lowers the price target from $32...

 genelux-q3-2024-gaap-eps-019-beats-020-estimate

Genelux (NASDAQ:GNLX) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.20) by 5 ...

 guggenheim-initiates-coverage-on-genelux-with-buy-rating-announces-price-target-of-8

Guggenheim analyst Kelsey Goodwin initiates coverage on Genelux (NASDAQ:GNLX) with a Buy rating and announces Price Target o...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION